| Mr James Joseph Devaney, PMHCNS | |
|
1345 Birch Ave, Cottage Grove, OR 97424-1416 | |
| (541) 942-3939 | |
| (541) 942-9310 |
| Full Name | Mr James Joseph Devaney |
|---|---|
| Gender | Male |
| Speciality | Clinical Nurse Specialist - Psychiatric/mental Health |
| Location | 1345 Birch Ave, Cottage Grove, Oregon |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316146624 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SP0808X | Clinical Nurse Specialist - Psychiatric/mental Health | 200570020CNS (Oregon) | Primary |
| Entity Name | Lane County Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326138314 PECOS PAC ID: 7416853833 Enrollment ID: O20040309000023 |
News Archive
A study by the University of Southampton examining non-pharmaceutical interventions (NPIs) in response to the new coronavirus (COVID-19) in China shows that a range of early, coordinated and targeted measures are needed to help significantly reduce its spread.
NxStage Medical, Inc., a leading manufacturer of innovative dialysis products, today reported financial results for the three months and twelve months ended December 31, 2009, that include revenue and Adjusted EBITDA results above the top end of its guidance ranges.
Women at the highest genetic risk for fracture benefit the most from hormone therapy, according to a first-of-its-kind study led by researchers at the University at Buffalo.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two oral presentations and two abstracts were delivered at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida. The presentations and abstracts highlighted clinical and preclinical progress with GlycoMimetics's lead compound GMI-1070, now in Phase 2 clinical trials in sickle cell crisis.
Australian researchers will aim to discover the proteins that cause multiple sclerosis (MS), thanks to a new nationwide research effort. The new research project will receive funding of $1 million over four years, starting this year, under the Australian Research Council's Linkage Projects funding scheme and from MS Research Australia (MSRA), the research arm of MS Australia.
› Verified 7 days ago
| Entity Name | Sequoia Mental Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730167982 PECOS PAC ID: 9436145661 Enrollment ID: O20040423000880 |
News Archive
A study by the University of Southampton examining non-pharmaceutical interventions (NPIs) in response to the new coronavirus (COVID-19) in China shows that a range of early, coordinated and targeted measures are needed to help significantly reduce its spread.
NxStage Medical, Inc., a leading manufacturer of innovative dialysis products, today reported financial results for the three months and twelve months ended December 31, 2009, that include revenue and Adjusted EBITDA results above the top end of its guidance ranges.
Women at the highest genetic risk for fracture benefit the most from hormone therapy, according to a first-of-its-kind study led by researchers at the University at Buffalo.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two oral presentations and two abstracts were delivered at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida. The presentations and abstracts highlighted clinical and preclinical progress with GlycoMimetics's lead compound GMI-1070, now in Phase 2 clinical trials in sickle cell crisis.
Australian researchers will aim to discover the proteins that cause multiple sclerosis (MS), thanks to a new nationwide research effort. The new research project will receive funding of $1 million over four years, starting this year, under the Australian Research Council's Linkage Projects funding scheme and from MS Research Australia (MSRA), the research arm of MS Australia.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr James Joseph Devaney, PMHCNS 1200 Hilyard St, Suite 460, Eugene, OR 97401-8122 Ph: (541) 685-1794 | Mr James Joseph Devaney, PMHCNS 1345 Birch Ave, Cottage Grove, OR 97424-1416 Ph: (541) 942-3939 |
News Archive
A study by the University of Southampton examining non-pharmaceutical interventions (NPIs) in response to the new coronavirus (COVID-19) in China shows that a range of early, coordinated and targeted measures are needed to help significantly reduce its spread.
NxStage Medical, Inc., a leading manufacturer of innovative dialysis products, today reported financial results for the three months and twelve months ended December 31, 2009, that include revenue and Adjusted EBITDA results above the top end of its guidance ranges.
Women at the highest genetic risk for fracture benefit the most from hormone therapy, according to a first-of-its-kind study led by researchers at the University at Buffalo.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two oral presentations and two abstracts were delivered at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida. The presentations and abstracts highlighted clinical and preclinical progress with GlycoMimetics's lead compound GMI-1070, now in Phase 2 clinical trials in sickle cell crisis.
Australian researchers will aim to discover the proteins that cause multiple sclerosis (MS), thanks to a new nationwide research effort. The new research project will receive funding of $1 million over four years, starting this year, under the Australian Research Council's Linkage Projects funding scheme and from MS Research Australia (MSRA), the research arm of MS Australia.
› Verified 7 days ago